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included gastric antral vascular ectasia (GAVE) (6), GAVE
and AD (6), tumor (9), polyps (2), Crohn’s disease (3), NSAID
ulceration (3), peptic ulcer disease (3), varices (2), small
bowel ulcers (4), Dieulafoy (1), and miscellaneous (11).
Carey described advanced age as the only predictive factor
in overt OGB. However, in our data set (using multivariate
analysis), both transfusion dependence (P = 0.005) and
co-morbidity (P < 0.0001) were significant predictive fac-
tors. The management was altered in 42% and 23% in the
overt bleeders and occult bleeders, respectively (P < 0.025).
This was in the form of endoscopic treatment of angioec-
tasia: heater probe (16), variceal glueing (1), polypectomy
(1), surgery (12), drug therapy (11: Helicobacter eradica-
tion/proton pump inhibitors [2], thalidomide [3], beta block-
ers [1], azathioprine [1]/withdrawal of nonsteroidal anti-
inflammatory drugs [4]), and initiation of a gluten-free diet
(1).
In conclusion, transfusion dependence and comorbidity
may also be significant predictors of a positive diagnostic
yield. Further CE studies are required to validate these crite-
ria, ensuring efficient use of the CE service.
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Isotretinoin and Inflammatory Bowel
Disease
TO THE EDITOR: We read with great interest the recent
review published in your Journal by Reddy et al., which
suggests a possible association between isotretinoin use and
inflammatory bowel disease (IBD) (1). Although IBD is de-
scribed as a possible adverse drug reaction in the product
information, little attention has been given in the literature to
this association.
In fact, we could not ignore the fact that the most com-
mon occurrence of isotretinoin prescription is in young adult-
hood, which also corresponds to the peak age for IBD on-
set. Knowing that abnormalities may not appear until months
to years after its discontinuation, the association with prior
isotretinoin use can easily go unnoticed (2). So, besides a
thorough history of IBD risk factors before isotretinoin pre-
scription, gastroenterologists must be aware of this fact and
ask for newly diagnosed patients with IBD about previous
isotretinoin use.
It is conceivable that isotretinoin can act as a trigger for
IBD in already predisposed individuals, or unmask symp-
toms in patients with preexisting subclinical disease (1, 2).
While no well-documented relationship between acne and
IBD exists, we might remember that other dermatologic le-
sions commonly included in the acne differential diagnosis
may be associated with IBD, being described as extraintesti-
nal manifestations, such as hidradenitis suppurativa (or acne
inversa) (3). Thus, we might consider these dermatologic le-
sions as the first manifestation of IBD. In these circumstances,
isotretinoin could be considered as neither acting as a trigger
nor unmasking subclinical disease.
This discussion is supported by our own personal experi-
ence, in a case concerning a 19-yr-old female who had been
on isotretinoin for genitofemoral acne inversa 20 mg/day for
a year. There were no other gastrointestinal disorders on her
previous medical and family history. One month before the
end of treatment, she developed persistent aqueous diarrhea
and progressive weight loss. Five months later, colonoscopy
revealed an aftoid ileocolitis and pathological examination
was compatible with Crohn’s disease. There was a significant
clinical improvement after starting oral mesalazine 3 g/day.
The relationship between isotretinoin and the emergence
of Crohn’s disease in this particular case, with no other risk
factors for IBD, is clear. However, could we assume that acne
inversa was not the first manifestation or a predisposing sign
for Crohn’s disease?
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